Generic Drug Patent Suits Up In 2017, Especially In Delaware

Law360 (May 3, 2018, 3:54 PM EDT) -- Patent suits involving generic drugs increased 29 percent in 2017 over the previous year, with a hefty 60 percent spike in Delaware, according to a Thursday report by Lex Machina, and attorneys say the Delaware numbers are likely tied to the U.S. Supreme Court’s TC Heartland ruling.

The legal analytics firm's annual report on litigation involving Abbreviated New Drug Applications under the Hatch-Waxman Act found that 417 ANDA suits were filed in 2017, up from 324 in 2016 but still below the 475 filed in 2015 and 437 filed in 2014. For several years before that, the number of ANDA suits...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!